About Us

Nektar Therapeutics is a global biopharmaceutical company focused on the discovery and development of novel therapies which selectively modulate the immune system to treat autoimmune disorders. We apply our deep understanding of immunology and unparalleled expertise in polymer chemistry to create one-of-a-kind, highly-selective medicines with optimal therapeutic benefit.

Our success is rooted in four key elements:

  • Our proven track record of discovering and delivering a portfolio of life-changing medicines globally commercialized by our pharmaceutical partners
  • Our deep understanding of immunology and unparalleled, long-standing expertise in polymer chemistry which fuel our discovery engine
  • Our targeted portfolio of one-of-a-kind, highly-selective therapeutics which modulate the immune system to advance the treatment of autoimmune disorders and chronic inflammatory conditions
  • Our team of dedicated scientists, clinicians, and employees dedicated to bringing new medicines to patients with debilitating diseases
Latest and Upcoming Investor Events


Mar 5, 2024 at 2:10 PM EST

Contact Nektar Investor Relations

Vivian Wu
Director, Investor Relations & Corporate Affairs
628-895-0661

Email

Transfer Agent and Stockholder Services

Computershare Shareholder Services
P.O. Box 43006
Providence, RI 02940-3006
(877) 290-2261
(201) 680-6578
www.computershare.com/investor